drugset
drugset / Trial / NCT07447050

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

NCT07447050 ↗

Phase 2 Recruiting 24 enrolled University of California, Irvine
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.

Timeline

Start
2025-12-23
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 50 mg Oral

Indications

breast cancer colorectal cancer gastric cancer head and neck cancer liver cancer lung cancer malignant urinary system neoplasm ovarian cancer sarcoma